Close

UPDATE: Jefferies Starts Paratek Pharmaceuticals (PRTK) at Buy, Sees 100%+ Upside

March 2, 2021 4:35 AM EST
Get Alerts PRTK Hot Sheet
Price: $2.08 -1.89%

Rating Summary:
    12 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 28 | New: 29
Join SI Premium – FREE
(Updated - March 2, 2021 7:38 AM EST)

Jefferies analyst Eun Yang initiates coverage on Paratek Pharmaceuticals (NASDAQ: PRTK) with a Buy rating and a price target of $15.00.

The analyst commented, "PRTK's Nuzyra launched in 2019 for serious skin infection & community-acquired pneumonia in hospital pts that fail generic tx. We expect expansion into the community setting in 2021 to fuel sales growth to ~$300M in '28 ($39M in '20). Nuzyra is also being tested in M. abscessus infection (no approved tx, ~$1B US mkt), providing further upside if successful. With anticipated sales growth & potential label expansion, we view current share price offers good value."

For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.

Shares of Paratek Pharmaceuticals closed at $7.16 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co